Proteus Announces Issuance of U.S. Patent for Digital Health Communications

REDWOOD CITY, Calif.--()--Proteus Biomedical Inc., a pioneer in digital health, announced today that the United States Patent Office will award U.S. Patent Number 8114021 to Proteus. The patent, entitled “Body Associated Receiver and Method,” is directed to the Proteus wearable and ingestible sensor technologies and related sensor devices used to create digital communication networks within, on and around the human body for health-related and other applications.

This patent is the 41st issued patent granted to the company. Proteus has over five hundred patents on digital health technologies and their uses pending or issued in the US and other countries.

Proteus develops digital health products that collect and aggregate various behavioral, physiologic and therapeutic metrics—such as medication adherence, heart rate, sleep patterns, physical activity and stress levels—into meaningful and appropriate personal management tools delivered to the mobile devices of consumers. Proteus recently announced the commercial launch of two product systems in 2012 based on its product platform—a remote body monitoring system called Metria™ by its partner Avery Dennison, and a digital health product for family care givers called Helius™ with its partner Lloydspharmacy. Both product systems represent leading examples of an emerging industry of digital health products in which sensor-enabled devices associated with the body continuously monitor and deliver personalized information to individuals.

“This patent describes devices worn on the body that communicate with other sensor-enabled devices in an optimal frequency band for body area communication networks,” said Mark Zdeblick, Chief Technical Officer at Proteus. “This bandwidth and the principle of body area communication are ideal for low power, relatively low bit rate communications for digital health products.”

About Proteus Biomedical, Inc.

Proteus Biomedical is pioneering digital health, an emerging field of advanced therapies that integrate in-body and on-body sensor and mobile communications technologies into existing pharmaceutical, medical device and consumer products. Proteus is developing and commercializing a range of digital health care products in partnership with global leaders from multiple industries, including Novartis, Medtronic, ON Semiconductor, Kaiser Permanente and Lloydspharmacy. Proteus is also establishing digital health technology standards by non-exclusively licensing aspects of its platform to an ecosystem of partners that embed Proteus innovations into their own branded products, including Avery Dennison and BodyMedia for the Metria™ line of wearable sensor products. More information about Proteus Biomedical can be found at www.proteusbiomed.com.

Contacts

Proteus Biomedical Inc.
Marnell Mullarkey, +1-650-632-4031
mmullarkey@proteusbiomed.com

Release Summary

Proteus Biomedical Inc., a pioneer in digital health, announced today that the United States Patent Office will award U.S. Patent Number 8114021 to Proteus.

Contacts

Proteus Biomedical Inc.
Marnell Mullarkey, +1-650-632-4031
mmullarkey@proteusbiomed.com